Due Diligence
How confident are you about the quality of the data supplied with your prospective in- licensed compounds? How confident are you about the value of your investment? In our experience, companies may find that the data is not as good as they have been led to believe, or they find themselves at regulatory risk because of serious non-compliance. This may result in expensive repeat studies. Adamas can:
- Conduct an independent assessment of the data that you are purchasing through a due diligence audit
- Assess the level of regulatory risk of serious non-compliance
- Help you to be more confident about the value of your investment
Watch More Adamas VideosDue Diligence
Pharmaceutical companies are facing increasing financial pressures to produce an acceptable return on investment (ROI).
The cost of drug development is increasing and the level of R&D productivity has declined. At the same time companies are facing cost containment measures by their payors.
Loss of patent rights for the larger selling pharmaceutical selling products adds financial pressure.
One of the many strategic options that pharmaceutical companies are adopting is to fill their R&D pipeline with in-licensed compounds from other companies.
Part of the process of in-licensing compounds is to manage the inherent risk. Increasingly, companies that in-license compounds that are under clinical development want to manage the risk by understanding more fully the clinical programme. Are the current programmes robust? Will any of the programmes need to be repeated?
ADAMAS has the team, the experience, the skills and the competencies to conduct independent due diligence of a clinical development programme to help companies understand and manage the associated risk.
Contact us to see how we could help you
Contact ADAMAS Consulting by email or
on +44 (0)1344 751 210 to discuss your individual requirements.
“This was a very enriching experience being inspected by you and your team last week. Overall we are very satisfied. Very good job”
H.R., Director R&D QA, Global Pharma
An Introduction to Adamas
Patricia Fitzgerald, CEO of Adamas Consulting talking on the Adamas Consulting's reason for being.
Business in Europe
Markus Wallstein, Director GmbH
at Adamas Consulting talking on how Adamas Consulting's global network covers Europe.
Our Global Capability
Vaska Tone, V.P. North American Operations at Adamas Consulting talking on Adamas Consulting's Global Capability.
Connect with Adamas
Connect with Adamas Consulting on our online communities.
Visit our Linked in page
Visit our YouTube channel
